2021
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.Peer-Reviewed Original ResearchConceptsObjective response rateImmune checkpoint inhibitorsProgression-free survivalEndometrial cancerWhole-exome sequencingSporadic endometrial cancerOverall survivalEnd pointPhase 2 pilot studyPrimary end pointSecondary end pointsTumor mutation burdenPhase 2 evaluationLarger confirmatory studiesAntigen processing/presentationProcessing/presentationCheckpoint inhibitorsSurgical resectionICI resistanceDMMR patientsPrognostic significanceDMMR tumorsMechanisms of resistanceLocal treatmentSporadic MSI
2019
Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer
Seifi F, Parkash V, Clark M, Menderes G, Tierney C, Silasi DA, Azodi M. Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: e2019.00021. PMID: 31285650, PMCID: PMC6596444, DOI: 10.4293/jsls.2019.00021.Peer-Reviewed Original ResearchConceptsLymphovascular space invasionEndometrial cancerSpace invasionEarly-stage endometrial cancerPatients meeting eligibility criteriaInvasive surgical stagingStage endometrial cancerRetrospective cohort studyBody mass indexMeeting eligibility criteriaPeritoneal cytologyAdjuvant radiotherapyAdjuvant therapyAdjuvant treatmentSurgical stagingCohort studyLymphovascular invasionSerous histologyPathologic evaluationMass indexGynecologic pathologistsSubgroup analysisTumor gradeUterine manipulatorIntrauterine manipulator
2017
519 Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical Junction
Seifi F, Clark M, Sami A, Azodi M. 519 Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical Junction. Journal Of Minimally Invasive Gynecology 2017, 24: s183. DOI: 10.1016/j.jmig.2017.08.547.Peer-Reviewed Original Research563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer
Seifi F, Davis M, Clark M, Paraiso E, Azodi M. 563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2017, 24: s184-s185. DOI: 10.1016/j.jmig.2017.08.591.Peer-Reviewed Original Research
2016
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesCyclin ECystadenocarcinoma, SerousEndometrial NeoplasmsEpothilonesExomeFemaleHumansMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalOncogene ProteinsPrognosisProtein Kinase InhibitorsProtein Phosphatase 2RadioimmunotherapyReceptor, ErbB-2Sequence Analysis, DNASignal TransductionTOR Serine-Threonine KinasesTubulin ModulatorsTumor Suppressor Protein p53Uterine NeoplasmsVascular Endothelial Growth Factor AConceptsUterine serous carcinomaEndometrial cancerSerous carcinomaTreatment of USCPIK3CA/AKT/mTOREndometrial cancer casesRecent whole-exome sequencing studiesHER2/neu geneNovel therapeutic targetAkt/mTORBiologic therapyAggressive variantDismal prognosisAggressive subtypeWhole-exome sequencing studiesCancer casesTherapeutic targetSubsequent deathDriver mutationsNeu geneGain of functionCarcinomaTherapyCancerSequencing studies